MINNEAPOLIS, MN — The SYMPLICITY HTN-3 trial, a phase 3 study testing catheter-based renal denervation for the treatment of resistant hypertension, failed to achieve its primary efficacy end point, ...
RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...
PARIS, France—Even though 6-month findings of the long-awaited SYMPLICITY HTN-3 randomized trial demonstrated little effect of renal denervation on blood pressure (BP), the study’s data can still ...
CHICAGO, IL—In the expanded SPYRAL HTN-ON MED trial, renal denervation with the Symplicity Spyral multielectrode catheter (Medtronic) failed to meet its primary endpoint in terms of blood ...
It's almost impossible to keep up with what things mean on TikTok, which is mostly thanks to the users who come up with phrases, memes, and acronyms almost daily. And when one sticks, you'd better be ...
RADNOR, Pa., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and ...
PARIS — Renal denervation provides meaningful blood pressure reductions in hypertensive patients taking up to three commonly used antihypertensive drugs, according to results from the sham-controlled ...
DUBLIN and CHICAGO, Nov. 7, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the six-month results from the full cohort of the SPYRAL HTN-ON MED ...
Mineralys Therapeutics announced the positive results of its Launch-HTN trial, the largest study of an aldosterone synthase inhibitor for patients with uncontrolled or treatment-resistant hypertension ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results